S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) - Part 2: Supportive therapy of EN in the acute and post-acute stages.

Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare, predominantly drug-induced, acute life-threatening diseases of skin and mucosae. SJS and TEN are nowadays considered as variants of one disease entity with varying degrees of severity called epidermal necrolysis (EN). EN is associated with high morbidity and mortality and constitutes a major disease burden for affected patients. The guideline "Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)" was developed under systematic consideration of existing scientific literature and in a formal consensus process according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF) to establish an evidence-based framework to support clinical decision-making. The interdisciplinary guideline commission consisted of representatives from various specialist societies and of patient representatives. The guideline is aimed at specialists in the fields of dermatology, ophthalmology, plastic surgery, intensive care, and pediatrics in hospitals and offices, as well as other medical specialties involved in the diagnosis and treatment of EN. The guideline is also aimed at patients, their relatives, insurance funds, and policymakers. The second part is concerned with the topics of supportive therapy in the acute phase of EN and outpatient follow-up treatment.

Paulmann M ，Heuer R ，Annecke T ，Behr B ，Boch K ，Boos AM ，Brockow K ，French LE ，Gille J ，Gundlach V ，Hartmann B ，Höger P ，Hofmann SC ，Klein T ，Lehnhardt M ，Liß Y ，Maier P ，Mandel P ，Marathovouniotis N ，Marlok F ，Mittelviefhaus H ，Pleyer U ，Pradeau M ，Rall K ，Rieg S ，Rittner H ，Sander F ，Schnitzler S ，Schut C ，Stolle A ，Vorobyev A ，Wedi B ，Weiss J ，Zepp M ，Ziemer M ，Mockenhaupt M ，Nast A ... -  《-》

S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) - Part 1: Diagnosis, initial management, and immunomodulating systemic therapy.

Heuer R ，Paulmann M ，Annecke T ，Behr B ，Boch K ，Boos AM ，Brockow K ，French LE ，Gille J ，Gundlach V ，Hartmann B ，Höger P ，Hofmann SC ，Klein T ，Lehnhardt M ，Liß Y ，Maier P ，Mandel P ，Marathovouniotis N ，Marlok F ，Mittelviefhaus H ，Pleyer U ，Pradeau M ，Rall K ，Rieg S ，Rittner H ，Sander F ，Schnitzler S ，Schut C ，Stolle A ，Vorobyev A ，Wedi B ，Weiss J ，Zepp M ，Ziemer M ，Mockenhaupt M ，Nast A ... -  《-》

Stevens-Johnson syndrome and toxic epidermal necrolysis-like eruptions in patients treated with immune checkpoint inhibitors: a systematic review.

Akpala CO ，Erfani YJ ，Young J ，Saeidi V ，Todd A ，Chelf C ，Philips EJ ，Alavi A ... -  《-》

Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.

Reece D ，Imrie K ，Stevens A ，Smith CA ，Hematology Disease Site Groupof Cancer Care Ontario’s Program in Evidence-based Care ... -  《Current Oncology》

Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.

Elwenspoek MM ，Thom H ，Sheppard AL ，Keeney E ，O'Donnell R ，Jackson J ，Roadevin C ，Dawson S ，Lane D ，Stubbs J ，Everitt H ，Watson JC ，Hay AD ，Gillett P ，Robins G ，Jones HE ，Mallett S ，Whiting PF ... -  《-》